Ameriprise’s 4D Molecular Therapeutics FDMT Stock Holding History

Ameriprise’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,395	Closed	-$210K	–	4108
2024 Q3	$210K	Buy	19,395 +1,960	+11%	+$32.5K	﹤0.01%	3740
2024 Q2	$366K	Buy	+17,435	New	+$437K	﹤0.01%	3534

Other funds holding FDMT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's FDMT Position: Q4 2024 in Review

Ameriprise sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 19,395 shares — an estimated $210K sold.

Ameriprise first reported a position in FDMT in Q2 2024 and held it in 2 quarters. The position peaked at $366K in Q2 2024. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

Ameriprise reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
Ameriprise sold 19,395 4D Molecular Therapeutics shares in Q4 2024, an estimated $210K.
Ameriprise first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 2 quarters.
Ameriprise's 4D Molecular Therapeutics position peaked at $366K in Q2 2024.
145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.